Kidney Cancer

The approval of Welireg, according to an expert at Massachusetts General Hospital, is “extremely important” and will “dramatically” change how certain von Hippel-Lindau-associated cancers are treated.

Frontline Keytruda plus Lenvima for advanced renal cell carcinoma is an effective treatment with life-prolonging benefits, although patients should be monitored for side effects that can be easily managed.

The FDA granted approval to Welireg for the treatment of patients with von Hippel-Lindau-associated kidney cancer, CNS hemangioblastomas and pancreatic neuroendocrine tumors.

Patients on Keytruda/Lenvima lived for an average of 23.9 months without their disease progressing, compared to those on a different treatment, with an average of 9.3 months.

The FDA will speed up the review of Keytruda to treat patients with kidney cancer after they’ve undergone surgery.

Post-menopausal women may be at an increased risk for kidney cancer if they are diagnosed with type 2 diabetes.

The risk for under- or over-treatment for kidney cancer may be higher in women, in addition to Black and Hispanic patients.

From the recurrence of congressman Jim Hagedorn’s kidney cancer to a 100-mile bike race for charity, here’s what’s happening in the cancer landscape this week.

The combination of Lenvima and Keytruda was associated with improvements in survival and response rates over Sutent alone in various subgroups of patients with advanced renal cell carcinoma.

At a median follow-up of almost two years, 88.5% of patients remained on study treatment.

From a man with late-stage cancer who has matching tattoos with over 400 strangers to a 78-year-old cancer survivor getting his black belt in Taekwondo, here’s what’s happening in the cancer landscape this week.

Use of the combination of Keytruda and Inlyta is associated with long-term survival benefits in patients with kidney cancer.

In patients with metastatic renal cell carcinoma whose disease failed to respond to two prior therapies, Fotivda, compared with Nexavar, contributed to a duration of response of 20.3 months versus 9 months.

Treatment with Keytruda following surgery was associated with a significant reduction in the risk of disease recurrence or death compared with placebo in patients with clear cell renal cell carcinoma.

The priority review will focus on the combination of Keytruda and Lenvima for the first-line treatment of advanced renal cell carcinoma, as well as the treatment of certain patients with endometrial carcinoma.

Recent data found an association between higher BMI and better overall survival among patients with metastatic renal cell carcinoma who were treated with immune checkpoint inhibitors.

Certain patients with metastatic renal cell carcinoma may benefit with active surveillance compared with systemic therapy for their management and may also lead to an improved quality of life.

Inlyta alone demonstrates longer progression-free survival compared to Inlyta in combination with carotuximab.

CURE spoke with Dr. Eric Jonasch about the National Comprehensive Cancer Network’s Category 1 recommendation for the combination use of Lenvima plus Keytruda for the treatment of front-line renal cell carcinoma. In particular, how it can impact a patient’s treatment journey.

The biggest reason the FDA’s recent approval of Fotivda is important for adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies, according to an expert from the Vanderbilt-Ingram Cancer Center, is that it offers them a very tolerable treatment option that may preserve quality of life.

In honor of Kidney Cancer Awareness Month, CURE® compiled some recent kidney cancer news and updates patients may have missed.

The agency granted approval to Fotivda in adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.

The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.

Positive results from the phase 3 CLEAR clinical trial, presented at the 2021 ASCO Genitourinary Cancers Symposium, are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma (RCC), says the study’s lead author, Dr. Robert J. Motzer.

In June 2020, Kayla Bulkley gave birth to her and her husband’s long-awaited baby girl, Jane. Within a month, Kayla was diagnosed with kidney cancer.